Nowadays, dupilumab, an antibody directed against the interleukin‐4 receptor subunit α (IL-4Rα), targeting other type 2 inflammatory diseases such as asthma and atopic dermatitis, is approved for the treatment of EoE. Here, IL4R is linked to eosinophilic esophagitis.